Annales pharmaceutiques francaises · 2026
The pharmacogenetics of Tacrolimus in Algerian kidney recipients' patients.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fetati Habiba, Abderahmene Amani, Boudia Fatma, Zemour Lakhdar, Mekaouche Nadjet-Fatima-Zohra, Memou Asmaa, Djoudad Kada, Zerdoumi Faiza, Benslama Ali, Omezzine Asma, Toumi Houari
Аннотация
BACKGROUND: The aim of this study was to evaluate the impact of CYP3A5*3(rs776746), CYP3A4*1B (rs2740574), CYP3A4*22 (rs35599367) and ABCB1 3435C>T (rs1045462) on Tacrolimus (Tac) pharmacokinetics in the Algerian kidney transplant population.
MATERIALS AND METHODS: A retrospective and prospective cross-sectional study on only adult kidney recipient patients of Algerian origin who were treated with Tacrolimus regardless of the post-transplant delay. The genotyping of the four polymorphisms was performed using the Polymerase Chain Reaction (PCR) followed by Restriction Fragment Length Polymorphism (RFLP). Exposure to Tac was expressed as the ratio between the concentration and weight-adjusted dose (C0/D).
RESULTS AND DISCUSSION: One hundred and nine kidney recipient patients were included in the study. The genotyping revealed that 67.92% of patients were homozygous mutants for the CYP3A5*3/*3, 71.29% of patients were homozygous mutants for the CYP3A4*1B/*1B, 97.25% of patients were homozygous wild-type (CYP3A4*1/*1) for the polymorphism CYP3A4*22 and 45.9% homozygous wild-type (CC) for the polymorphism ABCB1 3435C>T. Impact analysis of these polymorphisms on the dose and the C0/D ratio showed that only the CYP3A5*3 polymorphism had a significant impact on Tac dose and C0/D (P˂0.001). The CYP3A5 expressors (E) patients (genotypes *1/*1 and *1/*3) received a higher dose than non-expressors (genotype *3/*3) (0.096±0.059mg/Kg vs. 0.073±0.045mg/Kg) (P˂0.001) with an E/NE dose ratio of 1.31. The non-expressors (NE) patients (genotype *3/*3) received Tac doses less than or equal to 0.104mg/Kg (Cuttof value) (P˂0.001).
CONCLUSION: Only the CYP3A5*3 polymorphism influences the Tac pharmacokinetics in the Algerian kidney transplant population.
MATERIALS AND METHODS: A retrospective and prospective cross-sectional study on only adult kidney recipient patients of Algerian origin who were treated with Tacrolimus regardless of the post-transplant delay. The genotyping of the four polymorphisms was performed using the Polymerase Chain Reaction (PCR) followed by Restriction Fragment Length Polymorphism (RFLP). Exposure to Tac was expressed as the ratio between the concentration and weight-adjusted dose (C0/D).
RESULTS AND DISCUSSION: One hundred and nine kidney recipient patients were included in the study. The genotyping revealed that 67.92% of patients were homozygous mutants for the CYP3A5*3/*3, 71.29% of patients were homozygous mutants for the CYP3A4*1B/*1B, 97.25% of patients were homozygous wild-type (CYP3A4*1/*1) for the polymorphism CYP3A4*22 and 45.9% homozygous wild-type (CC) for the polymorphism ABCB1 3435C>T. Impact analysis of these polymorphisms on the dose and the C0/D ratio showed that only the CYP3A5*3 polymorphism had a significant impact on Tac dose and C0/D (P˂0.001). The CYP3A5 expressors (E) patients (genotypes *1/*1 and *1/*3) received a higher dose than non-expressors (genotype *3/*3) (0.096±0.059mg/Kg vs. 0.073±0.045mg/Kg) (P˂0.001) with an E/NE dose ratio of 1.31. The non-expressors (NE) patients (genotype *3/*3) received Tac doses less than or equal to 0.104mg/Kg (Cuttof value) (P˂0.001).
CONCLUSION: Only the CYP3A5*3 polymorphism influences the Tac pharmacokinetics in the Algerian kidney transplant population.